Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 0 | 0 |
% | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] Though the company has posted steady growth in its top and bottom lines, its tiny post-IPO paid-up equity capital indicates longer gestation for migration to the mainboard. Based on FY22 earnings, its IPO is priced aggressively. This pricy issue may be skipped. Read detail review...
EP Biocomposites IPO Reviews, analysis and views by popular members. Read EP Biocomposites Ltd. IPO reviews by retail investors to find recommended ipo to buy.
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% | 0.00 | 0.00 | 0.00 | 0.00 |
Member | Review |
---|---|
No recommendation found. Be the first to post the recommendation. |
Note: